UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Poll|Articles|April 2, 2024
Have You Seen the Translating Research Into Practice Column?
Author(s)Psychiatric Times Editors
Have you checked out the latest Translating Research Into Practice column? Let us know!
Advertisement
The Translating Research Into Practice (TRIP) column, edited by Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, is dedicated to reviewing the literature and sharing clinical implications.
Did you read the first installment, "Exploring the Role of Brexpiprazole in Alzheimer Dementia Agitation"?
If not, check it out here:
Did you read the second installment, "Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease"?
If not, check it out here:
Advertisement
Related to this article
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
Adjustment Disorder Is Hiding in Plain Sight
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5